- Norwegian Cruise Line Holdings’ stock surged after raising its annual profit forecast
- JPMorgan comments on cooling sentiment in earnings season: US stock retail investors shift to defensive positions, AI sector shows significant divergence
- Alphabet (GOOGL.US) shares plunge after earnings, but analysts remain bullish: AI and cloud business are long-term drivers
- Cadiz Raises $21 Million in Registered Direct Share Offering
- VEF’s Creditas Q3 revenue rises 34.9% to R$ 728.3 million
- BUZZ-Norwegian Cruise Line shares rise after raising full-year profit forecast
- Ameriprise Financial Announces Availability of Third-Quarter 2026 Earnings Release
- DT Midstream Reports Q3 Operating Earnings, Narrows 2026 Operating EPS Outlook
- --Earnings Flash (AMP) Ameriprise Financial Posts Q3 Adjusted Operating EPS Excluding Unlocking $12.07, vs. FactSet Est of $11.77
- Spot platinum touches the $1480 mark, down 4.07% intraday.
- Spot gold fell 1.16%. COMEX gold futures fell 0.49%.
- Mastercard Q3 Adjusted Earnings, Net Revenue Rise
- BlackRock Raises Total Voting Rights in Commerzbank to 4.38% From 4.33%
- Gilat Satellite Networks to Attend Deutsche Bank Global Space and Defense Tech Summit
- Annovis Bio participates in U.S. Biotech Day and Pharma Partnering Summit
- Kioson Komersial Indonesia Shareholder Meeting Fails to Reach Quorum
- Carter Bankshares Declares Quarterly Dividend of $0.10 Per Share
- Monster Beverage publishes update to financial calendar
- Eventer Technologies Adopts Semi-Annual Financial Reporting
- Rigel Pharmaceuticals schedules third-quarter results conference call
- Wolfspeed awards director Andreas W Mattes 7,415 restricted stock units
- WEHA Transportasi Indonesia 2026 Nine-Month Net Profit Falls to Rp 17.79 Billion; Net Sales Rise 11% to Rp 255.92 Billion
- Truist Securities Adjusts Price Target on Axogen to $60 From $53, Keeps Buy Rating
- UMB FINANCIAL CORPORATION <UMBF.O>: RAYMOND JAMES CUTS TARGET PRICE TO $148 FROM $165
- Guardant Health Welcomes Pennsylvania Law Expanding Colorectal Cancer Screening Coverage
- MediWound Schedules Third-Quarter Financial Results Release
- H2O America launches $325 million remarketable senior note offering
- Sweco Sweden Q3 EBITA rises 39%
- Shimmick updates financial calendar
- Incyte raises 2026 net sales forecast to $5.21 billion-$5.3 billion
- Morgan Stanley Adjusts Price Target on Align Technology to $175 From $188
- Leonardo DRS' Q3 Adjusted Earnings, Revenue Increase; Raises 2026 Guidance
- Morgan Stanley Adjusts Price Target on Baker Hughes to $68 From $70
- Alnylam Pharmaceuticals Says Co on Track to Achieve 2026 Fincl Guidance >ALNY
- Alnylam Pharmaceuticals Still Sees 2026 Net Product Revenue $4.7B-$5.1B >ALNY
- Alnylam Pharmaceuticals 3Q Adj EPS $16.26 >ALNY
- Enviri's Harsco Environmental Secures 10-Year Contract Renewal With Egypt's EZS
- Synergy Capital participates in fifth Egypt Mining Forum
- Vaxart Publishes Update to Financial Calendar
- Fluent Publishes Update to Financial Calendar
- Cognex Plans Presentations at Four Investor Conferences
- Intellia to Present Four-Year Lonvo-z Data in Hereditary Angioedema at ACAAI 2026
- Beyond Air Schedules Quarterly Financial Results Conference Call
- Corvus Pharmaceuticals to Report Third-Quarter Financial Results
- GSI Technology Attends 15th Annual ROTH Technology Conference
- Midera Food Processing Updates Financial Calendar
- BIOGEN <BIIB.O>: CANACCORD GENUITY RAISES TARGET PRICE TO $272 FROM $248
- BioHarvest Sciences Sets Third-Quarter Results Release and Earnings Call
- Reed's Schedules Third-Quarter Results Conference Call
- Alnylam Pharmaceuticals: On Track to Achieve 2026 Financial Guidance >ALNY
- Cheniere Energy Partners Q3 Earnings, Revenue Increase
- BorgWarner Wins Inverter Supply Contract for Global Automaker's Future Electric Vehicles
- Arbe Robotics Publishes Update to Financial Calendar
- Integer Holdings Q3 income from continuing operations falls 62% to $14.98 million
- TENABLE HOLDINGS, INC <TENB.O>: CANACCORD GENUITY RAISES TARGET PRICE TO $54 FROM $36
- Processa Pharmaceuticals Names Sheila Gujrathi Executive Chair
- Amplifon Shareholders Approve Capital Increase for GN Hearing Acquisition
- 2-Yr Benchmark Govt Yields - Germany vs Other Nations
- Canadian Goldfields Starts Airborne Geophysical Survey at Miminiska Gold Project in Ontario
- US Equity Futures Fall Pre-Bell As Fed Holds Rate Steady, Traders Assess Big Tech Earnings
- Processa Pharma: Cash Runway Expected to Fund Ops Into 2H of 2029 >PCSA
- 10-Yr Benchmark Govt Yields - Germany vs Other Nations
- 10-Yr Benchmark Govt Yields - U.S. vs Other Nations
- 2-Yr Benchmark Govt Yields - U.S. vs Other Nations
- KeyCorp Presents at BancAnalysts Association Conference
- TriMas Q3 net income more than doubles to $19.36 million; Q3 net sales rise 8% to $178.74 million
- Mastercard Announces Availability of Third-Quarter 2026 Earnings Release
- PROG HOLDINGS INC : RAYMOND JAMES CUTS TARGET PRICE TO $45 FROM $50
- Hanmi Financial Declares Fourth-Quarter Dividend of $0.28 a Share
- --GUIDANCE: (FSS) Federal Signal Expects 2026 Adjusted EPS Range $5.20 to $5.32, vs. FactSet Est of $5.23
- --GUIDANCE: (FSS) Federal Signal Expects 2026 Net Sales Range $2.61B - $2.64B, vs. FactSet Est of $2.64B
- ATI Q3 Adjusted Earnings, Revenue Rise; Lifts 2026 EPS Guidance
- --GUIDANCE: (ALNY) Alnylam Pharmaceuticals Expects 2026 Total Net Product Revenue Range $4.70B - $5.10B
- Arrow Financial 3Q Net Interest Income $48.7 M >AROW
- Processa Pharma Enters Research Collaboration of Novel, Oral Macrocyclic Peptide-Based Neonatal Fc Receptor Antagonist Program From Generian Pharma >PCSA
- Tiger Gold intersects 450.9 meters grading 0.6 g/t gold at Ceibal target
- Amplifon Names Scott Davis to Board, Effective Upon GN Hearing Deal Closing
- Nexxen Sets Third-Quarter Results Announcement
- River Road Resources completes LiDAR survey at Stobart gold project
- Alnylam Q3 2026 net income rises year over year to $2.17 billion
- Arrow Financial on Track to Realize About 95 % of Anticipated Cost Savings by 1Q 2027 >AROW
- TriMas Backs 2026 Adj EPS $1.60-Adj EPS $1.70 >TRS
- Processa Pharma: FDA Clears IND for Phase 2 Study of VT-7208 in Chronic Spontaneous Urticaria >PCSA
- Processa Pharma: Phase 2 Studies Planned in Food Allergy, Relapsing Multiple Sclerosis >PCSA
- --Earnings Flash (MA) Mastercard Posts Q3 Net Revenue $9.81B, vs. FactSet of $9.66B
- CrowdStrike Secures 70 Partner Sponsors for Sold-Out Fal.Con Conference
- FDA Clears Eloxx's Exaluren for Phase 2 Trial in ADPKD
- Inbest Prime IV Adds BME Growth-to-Scaleup Move to November 23 Shareholder Vote Agenda
- Establishment Labs Q3 net loss narrows to $10.71 million; Q3 revenue rises 34% to $71.99 million
- Inbest Prime II Adds Shareholder Vote on BME Growth-to-Scaleup Move to November 23 Agenda
- L.B. Foster Acquires Dulworth Operating Assets for About $52.2 Million
- Inbest Prime I Adds Shareholder Vote on BME Growth-to-Scaleup Move to November 23 Agenda
- Deep Isolation Sets Third-Quarter Earnings Release
- Inbest Prime VII Adds Nov. 23 Shareholder Vote to Ratify Move From BME Growth to BME Scaleup
- Archer Aviation Partners With ITA Airways to Develop Air Taxi Services in Italy
- U.S. Freight Spending Jumps 32.1% Year Over Year, U.S. Bank Index Shows
- GoldHaven Reaches 3,000 Meters Drilled at Magno Project in British Columbia
- Inbest Prime III Announces Extraordinary Shareholder Meeting
- INBEST Prime VIII Sets Nov. 23 Shareholder Vote to Ratify Move From BME Growth to BME Scaleup
- Patrick Industries Q3 2026 net income falls 40% year over year to $21.06 million
